Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2010-02-18
2011-10-25
Nolan, Jason M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
08044064
ABSTRACT:
The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.
REFERENCES:
patent: 5475110 (1995-12-01), Hudkins et al.
patent: 5591855 (1997-01-01), Hudkins et al.
patent: 5594009 (1997-01-01), Hudkins et al.
patent: 5616724 (1997-04-01), Hudkins et al.
patent: 5705511 (1998-01-01), Hudkins et al.
patent: 6630500 (2003-10-01), Gingrich et al.
patent: 7109229 (2006-09-01), Engler et al.
patent: 7241779 (2007-07-01), Hudkins et al.
patent: WO 96/11933 (1996-04-01), None
patent: WO 98/07433 (1998-02-01), None
patent: WO 00/47583 (2000-08-01), None
patent: WO 01/14380 (2001-03-01), None
patent: WO 02/017914 (2002-03-01), None
patent: WO 02/28861 (2002-04-01), None
patent: WO 02/28874 (2002-04-01), None
patent: WO 02/30942 (2002-04-01), None
patent: WO 02/092065 (2002-11-01), None
patent: 0 545 195 (2003-06-01), None
Schafer et al. Drug Discovery Today 2008, 13 (21/22), 913-916.
Horig et al. Journal of Translational Medicine 2004, 2(44).
*Hudkins, R.L., “Synthesis of indeno[2,1-α]pyrrolo[3,4-c]carbzole lactam regioisomers using ethyl cis-μ-cyanoacrylate as a dienophile and lactam precursor,” J.Heterocyclic Chemistry, 2003, 40, 135-142.
*J. Chem. Res., 1986, 1401-1445.
*Lehninger, A.L., “The amino acid building blocks of proteins,” The Molecular Basis of Cell Structure and Function,Biochemistry, 2ndEd. Worth Publishers, NY, 1975, 71-77.
*Peet, N., et al., “Synthesis of angular benzodipyrazoles and related systems,”Heterocycles, 1991, 32(1), 41-72.
*Wynne, J.H., et al., “Facile one-pot synthesis ofS-alkyl thiocarbamates,”J. Org. Chem., 2003, 68, 3733-3735.
*Angeles, et al., “Enzyme-linked immunosorbent assay for trkA tyrosine kinase activity,”Anal. Biochem., 1996, 236, 49-55.
*Dermer,Bio /Technology, 1994, 12, 320.
*Engler, T.A., et al., “Novel, potent and selective cynclin D1/CDK4 inhibitors: indolo[6,7-α]pyrrolo[3,4-c]carbazoles,”Bioorganic&Medicinal Chem. Letts., 2003, 13, 2261-2267.
*Freshney, R.I., Culture of Animal Cells—a Manual of Basic Technique, Alan R. Liss, Inc., 1983, p. 4.
*Gingrich, D.E., et al., “A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-α]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055,”J. Med. Chem., 2003, 46, 5375-5388.
*Hudkins, R.L., et al., “Synthesis of benzo[b]furano-[2,3-α]pyrrolo[3,4-c]carbazole-5, -7-dione,” J.Heterocyclic Chemistry, 2001, 38, 591-595.
*Laird, A.D., et al., “Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents,”Expert. Opin. Investig. Drugs, 2003, 12(1), 51-64.
*Merritt, S.E., et al., “The mixed lineage kinase DLK utilizes MKK7 and not MKK4 as substrate,”J. of Biol. Chem., 1999, 274(15), 10195-10202.
*Pitt, A.M., et al., “High throughput screening protein kinase assays optimized for reaction, binding, and detection totally within a 96-well plate,”J. of Biomol. Screening, 1996, 1(1), 47-51.
*Rotin, et al., “SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity biding site for SH2 domains of phospholipase C-γ,”EMBO J., 1992, 11(2), 559-567.
*Rovin, L.J., “Preformulation,”Remington's Pharmaceutical Sciences, 17thEd.,Mack Publishing Co., Easton, PA, 1985, Chapter 76, 1409-1423.
*Ruggeri, B., et al., “CEP-7055: A novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models,”Cancer Res., 2003, 63, 5978-5991.
*Sanchez-Martinez, C., et al., “Aryl[α]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors,”Bioorganic&Medicinal Chem. Letts., 2003, 13, 3835-3839.
*Schenone, P., et al., “Reaction of 2-dimethylaminomethylene-1,3-diones with dinucleophiles. I. Synthesis of 1,5-disubstituted 4-acylpyrazoles,”J. Heterocyclic Chem., 1982, 19, 1355-1361.
*Becknell et al.,Bioorganic&Med. Chem. Lett., 2006, 16, 5368-5372.
*Underiner et al.,Bioorganic&Med. Chem. Lett., 2008, 18, 2368-2372.
*Dandu et al.,Bioorganic&Med. Chem. Lett., 2008, 18, 1916-1921.
Becknell Nadine C.
Brown Peter D.
Hudkins Robert L.
Ruggeri Bruce A.
Zulli Allison L.
Cephalon Inc.
Nolan Jason M
LandOfFree
Fused pyrrolocarbazoles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused pyrrolocarbazoles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused pyrrolocarbazoles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4255416